Global Molecular Diagnostics In Pharmacogenomics Market

Molecular Diagnostics In Pharmacogenomics Market Summary

The Global Molecular Diagnostics In Pharmacogenomics Market Size Was Estimated at USD 678.2 Million in 2024 and is projected to Reach USD 1423.7 Million in 2035, Growing at a CAGR of 6.97% from 2025 to 2035. The market for molecular diagnostics in pharmacogenomics is expanding as a result of rising demand for personalized medication, more knowledge of the advantages of early disease identification, higher frequency of chronic diseases, and technological developments in genome sequencing and bioinformatics.

Key Regional and Segment-Wise Insights

• In 2024, North America held the biggest revenue share of 37.36%, dominating the market.
• With the most revenue share of 47.37% in 2024, the kits and assays segment dominated the market based on product.
• In 2024, the infectious diseases segment held the greatest revenue share and led the market based on therapeutic area.

Global Market Forecast and Revenue Outlook

• 2024 Market Size: USD 678.2 Million
• 2035 Projected Market Size: USD 1423.7 Million
• CAGR (2025-2035): 6.97%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

The market for molecular diagnostics in pharmacogenomics focuses on using molecular diagnostic techniques to explore genetic effects on drug response patterns. Personalized medicine depends on this area since it enables doctors to select better and more successful treatments through genetic testing. The primary driving forces include rising chronic disease prevalence and the need for precise treatments, together with enhanced understanding of medication side effects. The shift toward customized treatment plans within cardiology and neurology, and oncology fields propels pharmacogenomic testing adoption at an increasing rate. The adoption of molecular diagnostics into routine medical procedures occurs because healthcare systems need to lower their costs and improve patient health outcomes.

The market shows continuous growth because of technological progress that advances real-time PCR, along with NGS and microarray technologies, to make genetic testing faster and more accurate and affordable. Test interpretation and clinical decision-making have been further enhanced by the creation of companion diagnostics and the use of AI and bioinformatics techniques. Government initiatives that support genomics, together with precision medicine research like the U.S. Precision Medicine Initiative, along with European and Asian programs, drive innovation and market penetration. The worldwide market growth receives support from financial incentives, together with regulatory structures.

Product Insights

What made the Kits and Assays Segment Capture a 47.37% Revenue Share in the Molecular Diagnostics in Pharmacogenomics Market in 2024?

The kits and assays segment held the largest revenue share of 47.37% and led the molecular diagnostics in pharmacogenomics market during 2024. The tools maintain their lead because clinical labs, together with research facilities, depend on them for fast, accurate genetic testing. The tools deliver standardized testing solutions that both help labs work faster and produce consistent test results. The rising popularity of pharmacogenomic testing kits appears mainly in oncology and chronic disease treatment because of the increasing demand for personalized healthcare approaches. The market success of these products stems from their improved design, increased sensitivity, and their automated system compatibility, which has boosted their operational efficiency.

The reagents segment within molecular diagnostics in the pharmacogenomics market will experience the fastest CAGR throughout the forecast period. The rising demand for reliable, high-quality reagents across different molecular testing methods, including next-generation sequencing (NGS), PCR, and genotyping assays, drives this growing trend. The precise and accurate diagnostic outcomes depend on reagents, which remain essential for both clinical and research operations. The growing interest in personalized healthcare, together with increased genetic testing volumes and advances in reagent development methods, drives this rising need for reagents. Market growth will accelerate due to manufacturers developing reagent products that support automated high-throughput testing operations.

Therapeutic Area Insights

Why Did the Infectious Diseases Segment Lead the Molecular Diagnostics in Pharmacogenomics Market in 2024?

The infectious diseases segment dominated the molecular diagnostics in pharmacogenomics market by generating the highest revenue share during 2024. The primary reason for this market supremacy stems from growing requirements of personalized treatment approaches to combat infectious illnesses, while antibiotic resistance continues to increase. Medical professionals achieve better treatment success through pharmacogenomic testing by tailoring antimicrobial therapies to patients' genetic profiles and simultaneously minimizing adverse drug reactions. The increasing frequency of infectious diseases such as HIV, hepatitis, and tuberculosis, combined with the requirement for precise diagnostic tools, drives the segment's expansion. The continued investigation, together with technological progress and worldwide health initiatives that focus on disease tracking and personalized healthcare approaches, strengthens the relationship between molecular diagnostics and infectious disease treatment.

The oncology segment within molecular diagnostics in the pharmacogenomics market will demonstrate the fastest CAGR during the forecast period. The increasing attention towards personalized cancer treatment using pharmacogenomic analysis to detect genetic changes and determine suitable, precise therapies represents the key driver of this market expansion.  The rising cancer occurrence worldwide, together with growing healthcare provider and patient understanding about genetic profiling, makes this method necessary for diagnosis. Next-generation sequencing (NGS), together with companion diagnostics, represents technological advancements that support this market expansion. The market experiences rapid growth because molecular diagnostics in oncology receives faster adoption due to regulatory approvals for targeted cancer therapies alongside continuous tumor genome studies.

Regional Insights

In 2024, North America leads the molecular diagnostics in pharmacogenomics market by generating the largest revenue share of 37.36%. The leading position of this region stems from three main factors: strong adoption of personalized medicine, numerous significant industry players in the area, and advanced healthcare infrastructure. The United States leads clinical practice implementation of pharmacogenomic testing due to its beneficial payment structures and regulatory systems.  Substantial R&D funding and Precision Medicine Initiative programs accelerate both research and commercial growth. The growing awareness among patients and healthcare providers, together with the increasing number of hereditary and chronic diseases, continues to fuel the demand for molecular diagnostics in pharmacogenomics.

Europe Molecular Diagnostics in Pharmacogenomics Market Trends

The European molecular diagnostics in pharmacogenomics market will experience a consistent CAGR during the forecast period. The growth in this market stems from Europe's expanding interest in personalized treatment approaches and increasing rates of chronic and genetic conditions, and medical professionals learning more about pharmacogenomic testing. European nations continue to adopt genetic testing for regular healthcare through their national genomics programs and precision medicine research financing.  The market expands because of the advanced healthcare infrastructure adjacent to academic research centers and regulatory frameworks that back innovative diagnostic tools. Public-private partnerships, together with the increasing use of next-generation sequencing technologies, will drive stable and long-lasting market development throughout Europe.

Asia Pacific Molecular Diagnostics in Pharmacogenomics Market Trends

The Asia Pacific molecular diagnostics in pharmacogenomics market will experience the fastest CAGR during the forecast period. The rapid growth of this market stems from increasing cases of chronic and hereditary diseases, along with rising healthcare spending and expanding understanding of personalized medicine across the region. Molecular diagnostic technology advances through government initiatives and expanding research facilities, which benefit China, India, and Japan, among other nations. The growing accessibility of genetic testing services, together with large patient numbers and improved healthcare systems, drives market adoption forward. Asia Pacific stands as a leading developing region within the global pharmacogenomics market because of partnerships between research institutes and pharmaceutical corporations that drive innovation alongside accessibility.

Key Molecular Diagnostics In Pharmacogenomics Companies:

The following are the leading companies in the molecular diagnostics in pharmacogenomics market. These companies collectively hold the largest market share and dictate industry trends.

• Roche Diagnostics
• Myriad Genetics
• Abbott Molecular
• QIAGEN
• Genomind
• Illumina, Inc.
• OneOme
• Thermo Fisher Scientific
• Agilent Technologies
• Invitae (formerly YouScript)
• Others

Recent Developments

• In April 2025, Tempus AI and Illumina established a strategic alliance to advance genetic innovation powered by AI in precision medicine.  Through the integration of Tempus's real-world multimodal data with Illumina's AI-enabled sequencing systems, our partnership aims to increase the clinical value of molecular diagnoses in pharmacogenomics.  The program facilitates the wider use of PGx diagnostics in therapeutic domains like neurology, cardiology, and oncology by improving data-informed drug selection techniques, producing solid clinical evidence, and optimizing regulatory routes.
• In February 2025, A Memorandum of Understanding was signed by Global Precision Diagnostics, Sunway Multicare Pharmacy, and ReGen Rehab Hospital to provide clinical pharmacogenomic services in Malaysia.  The partnership's main goals are to increase access to PGx testing via the PRECISE Pharmacogenomics platform and to integrate molecular diagnostics into pharmacy and rehabilitative care settings to facilitate safer and more individualized therapy.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the molecular diagnostics in pharmacogenomics market based on the below-mentioned segments:  

Global Molecular Diagnostics In Pharmacogenomics Market, By Product

• Kits and assays
• Reagents
• Services

Global Molecular Diagnostics In Pharmacogenomics Market, By Therapeutic Area

• Oncology
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

Global Molecular Diagnostics In Pharmacogenomics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa